Novo Nordisk Shares Face Mounting Pressure as Setbacks Pile Up

Novo Nordisk DK0062498333

Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters following a series of damaging developments. Investors are growing increasingly concerned as the maker of blockbuster drugs Ozempic and Wegovy confronts multiple challenges simultaneously, raising questions about the sustainability of its previous growth trajectory.

Thursday delivered a dual blow to the company’s prospects. First, research firm Morningstar substantially reduced its fair value estimate for Novo Nordisk shares, citing intensifying pricing pressures within the U.S. obesity medication market. The firm indicated that recent pricing agreements with the U.S. government would likely impact the company’s financial performance sooner than previously anticipated.